MAYNE Pharma Group has acquired generic Efudex (fluorouacil cream 5%) from Spear Pharmaceuticals in the USA.
The US$20 million price tag includes $16m in cash plus $4m in Mayne Pharma shares, while there is also a payment of up to $10m "contingent upon competitive dynamics in the product market over the next three years".
The deal also comprises a long-term supply agreement with the current US-based manufacturer, ensuring supply chain continuity.
Generic Efudex is an antineoplastic topical cream indicated for the treatment of solar keratoses and superficial basal skin cell carcinomas when conventional treatment methods are impractical.
Mayne ceo Scott Richards said Efudex was a strong strategic fit with the company's existing portfolio of dermatology products.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 18
